JNJ.US Johnson & Johnson

Healthcare Pharmaceuticals USA Stocks
285.75 USD
Close of Nov 15, 2026
194.15 288.11
Market cap
USD 688B
P/E
43.4x
P/B
8.44x
ROE
18.0%
Dividend yield
1.80%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is JNJ.US undervalued?

Graham number

The Graham number of Johnson & Johnson cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Johnson & Johnson fundamental analysis

No fundamental analysis for Johnson & Johnson yet.

Johnson & Johnson stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers,…

Full company profile